Hemophilia A

4 protocols meet the specified criteria


Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years with severe hemophilia A (FVIII < 1%)


A randomized, multicenter, open-label, phase iii clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic Emicizumab versus no prophylaxis in hemophilia a patients age >= 12 years without FVIII inhibitors


Evaluation of Joint Arthropathy Using Ultrasound Technique in Children With Severe Hemophilia Undergoing Prophylaxis Regimen


A Phase IV Multicenter, Single-Arm, Open Label Study of Emicizumab Prophylaxis in Patients with Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures.